Skip to main content
SpringerLink
Log in
Book cover

Polyomaviruses and Human Diseases pp 228–254Cite as

Pharmacotherapeutic Options for the Management of Human Polyomaviruses

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 577))

Abstract

Polyomaviruses [BK virus (BKV), JC virus (JCV) and simian virus 40 (SV40)] have been known to be associated with diseases in humans for over thirty years. BKV-associated nephropathy and JCV-induced progressive multifocal leukoencephalopathy (PML) were for many years rare diseases occurring only in patients with underlying severe impaired immunity. Over the past decade, the use of more potent immunosuppression (IS) in transplantation, and the Acquired Immune Deficiency Syndrome (AIDS) epidemic, have coincided with a significant increase in the prevalence of these viral complications. Prophylactic and therapeutic interventions for human polyomavirus diseases are limited by our current understanding of polyomaviral pathogenesis. Clinical trials are limited by small numbers of patients affected with clinically significant diseases, lack of defined risk factors and disease definitions, no proven effective treatment and the overall significant morbidity and mortality associated with these diseases. This chapter will focus on a review of the current and future research related to therapeutic targets and interventions for polyomavirus-associated diseases.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Shah KV. Polyomaviruses. In: Fields BN, Knipe DM, eds. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven, 1996:2027–43.

    Google Scholar 

  2. Gardner SD, Field AM, Coleman DV et al. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971; 1(7712):1253–7.

    PubMed  CAS  Google Scholar 

  3. Padgett BL, Walker DL, ZuRhein GM et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971; 1(7712):1257–60.

    PubMed  CAS  Google Scholar 

  4. Knowles W. The epidemiology of BK virus and the occurence of antigenic and genomic subtypes. In: Khalili K, Stoner GL, eds. Human Polyomaviruses: Molecular and Clinical Perspectives. New York: Wiley-Liss, 2001:527–60.

    Google Scholar 

  5. Major EO. Human polyomavirus. In: Knipe DM, Howley PM, eds. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001:2:2175–96.

    Google Scholar 

  6. Houff SA, Major EO, Katz DA et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988; 318(5):301–5.

    PubMed  CAS  Google Scholar 

  7. Kahan AV, Coleman DV, Koss LG. Activation of human polyomavirus infection — detection by cytologic techniques. Am J Clin Pathol 1980; 74:326–32.

    PubMed  CAS  Google Scholar 

  8. Coleman DV, Wolfendale MR, Daniel RA et al. A prospective study of human polyomavirus infection in pregnancy. J Infect Dis 1980; 142(1):1–8.

    PubMed  CAS  Google Scholar 

  9. Agha IA, Brennan DC. BK virus and current immunosuppressive therapy. Graft 2002; 5(Suppl):S65–72.

    Google Scholar 

  10. Hirsch HH, Knowles W, Dickenmann M et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347(7):488–96.

    PubMed  Google Scholar 

  11. Mylonakis E, Goes N, Rubin RH et al. BK virus in solid organ transplant recipients: An emerging syndrome. Transplantation 2001; 72(10):1587–92.

    PubMed  CAS  Google Scholar 

  12. Domes K, Loeber G, Meixensberger J. Association of polyomaviruses JC, SV40, and BK with human brain tumors. Virology 1987; 160(1):268–70.

    Google Scholar 

  13. Del Valle L, Gordon J, Enam S et al. Expression of human neurotropic polyomavirus JCV late gene product agnoprotein in human medulloblastoma. J Natl Cancer Inst 2002; 94(4):267–73.

    PubMed  Google Scholar 

  14. Khalili K. Human neurotropic JC virus and its association with brain tumors. Dis Markers 2001; 17(3):143–7.

    PubMed  CAS  Google Scholar 

  15. Boldorini R, Pagani E, Car PG et al. Molecular characterisation of JC virus strains detected in human brain tumours. Pathology 2003; 35(3):248–53.

    PubMed  CAS  Google Scholar 

  16. Laghi L, Randolph AE, Chauhan DP et al. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc Natl Acad Sci USA 1999; 96(13):7484–9.

    PubMed  CAS  Google Scholar 

  17. Safak M, Khalili K. An overview: Human polyomavirus JC virus and its associated disorders. J Neurovirol 2003; 9(Suppl 1):3–9.

    PubMed  CAS  Google Scholar 

  18. Corral I, Quereda C, Hellin T et al. Relapsing and remitting leukoencephalopathy associated with chronic HIV infection. Eur Neurol 2002; 48(1):39–41.

    PubMed  Google Scholar 

  19. White FA, Ishaq M, Stoner GL et al. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol 1992; 66(10):5726–34.

    PubMed  Google Scholar 

  20. Joseph J, Major EO. Basic, clinical, and epidemiological studies of progressive multifocal leukoencephalopathy: Implications for therapy. J Neurovirol 2003; 9(Suppl 1):1–2.

    PubMed  Google Scholar 

  21. Atwood WJ. Cellular receptors for the polyomaviruses. In: Khalili K, Stoner G, eds. Human Polyomaviruses: Molecular and Clinical Perspectives. New York: Wiley-Liss, 2001:53–72.

    Google Scholar 

  22. Mahmut S, Khalili K. An overview: Human polyomavirus JC virus and its associated disorders. J Neurovirol 2003; 9(Suppl 1):3–9.

    Google Scholar 

  23. Berger JR, Nath A. Clinical progressive multifocal leukoencephalopathy: Diagnosis and treatment. In: Khalili K, Stoner G, eds. Human Polyomaviruses: Molecular and Clinical Perspectives. New York: Wiley-Liss, 2001:237–56.

    Google Scholar 

  24. Koralnik IJ, Du Pasquier RA, Kuroda MJ et al. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 2002; 168(1):499–504.

    PubMed  CAS  Google Scholar 

  25. Du Pasquier RA, Kuroda MJ, Schmitz JE et al. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J Virol 2003; 77(22):11918–26.

    PubMed  Google Scholar 

  26. Clifford DB, Yiannoutsos C, Glicksman M et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999; 52(3):623–5.

    PubMed  CAS  Google Scholar 

  27. Berger JR, Levy RM, Flomenhoft D et al. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998; 44(3):341–9.

    PubMed  CAS  Google Scholar 

  28. Weber F, Goldmann C, Kramer M et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol 2001; 49(5):636–42.

    PubMed  CAS  Google Scholar 

  29. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: Harmful or beneficial? J Neurovirol 2003; 9(Suppl 1):25–31.

    PubMed  Google Scholar 

  30. Cinque P, Pierotti C, Vigano MG et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7(4):358–63.

    PubMed  CAS  Google Scholar 

  31. Cinque P, Bossolasco S, Brambilla AM et al. The effect of highly active antiretroviral theapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: Study of 43 cases with reveiw of the literature. J Neurovirol 2003; 9(Suppl 1):73–80.

    PubMed  CAS  Google Scholar 

  32. Berger JR, Concha M. Progressive multifocal leukoencephalopathy: The evolution of a disease once considered rare. J Neurovirol 1995; 1(1):5–18.

    PubMed  CAS  Google Scholar 

  33. Berger JR. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: Explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neurovirol 2003; 9(Suppl 1):38–41.

    PubMed  CAS  Google Scholar 

  34. Berger JR, Chauhan A, Galey D et al. Epidemiological evidence and molecular basis of interactions between HIV and JC virus. J Neurovirol 2001; 7(4):329–38.

    PubMed  CAS  Google Scholar 

  35. Seth P, Diaz F, Major EO. Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9(2):236–46.

    PubMed  CAS  Google Scholar 

  36. Royal W, Dupont B, McGuire D et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9(3):411–9.

    PubMed  CAS  Google Scholar 

  37. Marra CM, Rajicic N, Barker DE et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. Aids 2002; 16(13):1791–7.

    PubMed  CAS  Google Scholar 

  38. Hall CD, Dafni U, Simpson D et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 1998; 338(19):1345–51.

    PubMed  CAS  Google Scholar 

  39. Geschwind MD, Skolasky RI, Royal WS et al. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 2001; 7(4):353–7.

    PubMed  CAS  Google Scholar 

  40. Gasnault J, Kousignian P, Kahraman M et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: A monocenter observational study with clinical and JC virus load monitoring. J Neurovirol 2001; 7(4):375–81.

    PubMed  CAS  Google Scholar 

  41. De Luca A, Giancola ML, Ammassari A et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 2000; 182(4):1077–83.

    PubMed  Google Scholar 

  42. De Luca A, Ammassari A, Cingolani A et al. Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy. Aids 1998; 12(14):1937–8.

    PubMed  Google Scholar 

  43. Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: Defining a consensus terminology. J Neurovirol 2003; 9(Suppl 1):88–92.

    PubMed  CAS  Google Scholar 

  44. Yiannoutsos C, De Luca A. Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7:369–74.

    PubMed  CAS  Google Scholar 

  45. Reploeg MD, Storch GA, Clifford DB. BK virus: A clinical review. Clin Infect Dis 2001; 33(2):191–202.

    PubMed  CAS  Google Scholar 

  46. Hirsch HH, Mohaupt M, Klimkait T. Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy. J Infect Dis 2001; 184(11):1494–5, author reply 5–6.

    PubMed  CAS  Google Scholar 

  47. Randhawa PS, Finkelstein S, Scantlebury V et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999; 67(1):103–9.

    PubMed  CAS  Google Scholar 

  48. Haririan A, Klassen D. BK virus infection after nonrenal transplantation. Graft 2002; 5(Suppl):S58–S64.

    Google Scholar 

  49. Arthur RR, Shah KV, Baust SJ et al. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med 1986; 315(4):230–4.

    PubMed  CAS  Google Scholar 

  50. Leung AY, Mak R, Lie AK, et al. Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Bone Marrow Transplant 2002; 29(6):509–13.

    PubMed  CAS  Google Scholar 

  51. Gonzalez-Fraile MI, Canizo C, Caballero D, et al. Cidofovir treatment of human polyomavirus-associated acute haemorrhagic cystitis. Transpl Infect Dis 2001; 3(1):44–6.

    PubMed  CAS  Google Scholar 

  52. Garderet L, Bittencourt H, Sebe P et al. Cystectomy for severe hemorrhagic cystitis in allogeneic stem cell transplant recipients. Transplantation 2000; 70(12):1807–11.

    PubMed  CAS  Google Scholar 

  53. Kawakami M, Ueda S, Maeda T et al. Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 20(6):485–90.

    PubMed  CAS  Google Scholar 

  54. Goddard AG, Saha V. Late-onset hemorrhagic cystitis following bone marrow transplantation: A case report. Pediatr Hematol Oncol 1997; 14(3):273–5.

    PubMed  CAS  Google Scholar 

  55. Laszlo D, Bosi A, Guidi S et al. Prostaglandin E2 bladder instillation for the treatment of hemorrhagic cystitis after allogeneic bone marrow transplantation. Haematologica 1995; 80(5):421–5.

    PubMed  CAS  Google Scholar 

  56. Randhawa P, Baksh F, Aoki N et al. JC virus infection in allograft kidneys: Analysis by polymerase chain reaction and immunohistochemistry. Transplantation 2001; 71(9):1300–3.

    PubMed  CAS  Google Scholar 

  57. Li RM, Mannon RB, Kleiner D et al. BK virus and SV40 coinfection in polyomavirus nephropathy. Transplantation 2002; 74(11):1497–504.

    PubMed  Google Scholar 

  58. Trofe J, Cavallo T, First MR et al. Polyomavirus in kidney and kidney-pancreas transplantation: A defined protocol for immunosuppression reduction and histologic monitoring. Transplant Proc 2002; 34(5):1788–9.

    PubMed  Google Scholar 

  59. Randhawa PS, Demetris AJ. Nephropathy due to polyomavirus type BK. N Engl J Med 2000; 342(18):1361–3.

    PubMed  CAS  Google Scholar 

  60. Trofe J, Gaber LW, Stratta RJ et al. Polyomavirus in kidney and kidney-pancreas transplant recipe ents. Transpl Infect Dis 2003; 5(1):21–8.

    PubMed  CAS  Google Scholar 

  61. Ginevri F, De Santis R, Comoli P et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: A single-center analysis of incidence, risk factors, and novel therapeutic approaches. Trans plantation 2003; 75(8):1266–70.

    CAS  Google Scholar 

  62. Howell DN, Smith SR, Butterly DW et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999; 68(9):1279–88.

    PubMed  CAS  Google Scholar 

  63. Binet I, Nickeleit V, Hirsch HH et al. Polyomavirus disease under new immunosuppressive drugs: A cause of renal graft dysfunction and graft loss. Transplantation 1999; 67(6):918–22.

    PubMed  CAS  Google Scholar 

  64. Nickeleit V, Hirsch HH, Binet IF et al. Polyomavirus infection of renal allograft recipients: From latent infection to manifest disease. J Am Soc Nephrol 1999; 10(5):1080–9.

    PubMed  CAS  Google Scholar 

  65. Nickeleit V, Hirsch HH, Zeiler M et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000; 15(3):324–32.

    PubMed  CAS  Google Scholar 

  66. Nickeleit V, Klimkait T, Binet IF et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000; 342(18):1309–15.

    PubMed  CAS  Google Scholar 

  67. Binet I, Nickeleit V, Hirsch HH. Polyomavirus infections in transplant recipients. Current Opin ions in Organ Transplantation 2000; 5:210–16.

    Google Scholar 

  68. Ahuja M, Cohen EP, Dayer AM et al. Polyoma virus infection after renal transplantation. Use of immunostaining as a guide to diagnosis. Transplantation 2001; 71(7):896–9.

    PubMed  CAS  Google Scholar 

  69. Barri YM, Ahmad I, Ketel BL et al. Polyoma viral infection in renal transplantation: The role of immunosuppressive therapy. Clin Transplant 2001; 15(4):240–6.

    PubMed  CAS  Google Scholar 

  70. Buehrig CK, Lager DJ, Stegall MD et al. Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 2003; 64(2):665–73.

    PubMed  Google Scholar 

  71. Poduval RD, Kadambi P, Javaid B et al. Leflunomide-a potential new therapeutic agent for BK nephropathy. Am J Transplant 2003; 3(Suppl 5):189, (Abstract 44).

    Google Scholar 

  72. Mengel M, Marwedel M, Radermacher J et al. Incidence of polyomavirus-nephropathy in renal allografts: Influence of modern immunosuppressive drugs. Nephrol Dial Transplant 2003; 18(6):1190–6.

    PubMed  CAS  Google Scholar 

  73. Fishman JA. BK virus nephropathy—polyomavirus adding insult to injury. N Engl J Med 2002; 347(7):527–30.

    PubMed  Google Scholar 

  74. Hirsch HH, Steiger J. Polyomavirus BK. The Lancet Infectious Diseases 2003; 3(10):611–23.

    PubMed  Google Scholar 

  75. Kazory A, Ducloux D. Renal transplantation and polyomavirus infection: Recent clinical facts and controversies. Transpl Infect Dis 2003; 5(2):65–71.

    PubMed  CAS  Google Scholar 

  76. Nickeleit V, Steiger J, Mihatsch MJ. BK virus infection after kidney transplantation. Graft 2002; 5(Suppl):S46–57.

    Google Scholar 

  77. Nickeleit V, Singh H, Mihatsch M. Polyomavirus nephropathy: Morphology, pathophysiology, and clinical management. Curr Opin Nephrol Hypertens 2003; 12(6):599–605.

    PubMed  Google Scholar 

  78. Ramos E, Drachenberg CB, Papadimitriou JC et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13(8):2145–51.

    PubMed  Google Scholar 

  79. Drachenberg RC, Drachenberg CB, Papadimitriou JC et al. Morphological spectrum of polyoma virus disease in renal allografts: Diagnostic accuracy of urine cytology. Am J Transplant 2001; 1(4):373–81.

    PubMed  CAS  Google Scholar 

  80. Celik B, Shapiro R, Vats A et al. Polyomavirus allograft nephropathy: Sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression. Am J Transplant 2003; 3(11):1378–82.

    PubMed  Google Scholar 

  81. Drachenberg CB, Beskow CO, Cangro CB et al. Human polyoma virus in renal allograft biopsies: Morphological findings and correlation with urine cytology. Hum Pathol 1999; 30(8):970–7.

    PubMed  CAS  Google Scholar 

  82. Hussain S, Bresnahan BA, Cohen EP et al. Rapid kidney allograft failure in patients with polyoma virus nephritis with prior treatment with antilymphocyte agents. Clin Transplant 2002; 16(1):43–7.

    PubMed  Google Scholar 

  83. Hurault de Ligny B, Etienne I, Francois A et al. Polyomavirus-induced acute tubulo-interstitial nephritis in renal allograft recipients. Transplant Proc 2000; 32(8):2760–1.

    PubMed  CAS  Google Scholar 

  84. Rahamimov R, Lustiga S, Tovar A et al. BK polyoma virus nephropathy in kidney transplant recipient: The role of new immunosuppressive agents. Transplant Proc 2003; 35(2):604–5.

    PubMed  CAS  Google Scholar 

  85. Atwood WJ, Norkin LC. Class I major histocompatibility proteins as cell surface receptors for simian virus 40. J Virol 1989; 63(10):4474–7.

    PubMed  CAS  Google Scholar 

  86. Liu CK, Wei G, Atwood WJ. Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2–6)-linked sialic acids. J Virol 1998; 72(6):4643–9.

    PubMed  CAS  Google Scholar 

  87. Liu CK, Hope AP, Atwood WJ. The human polyomavirus, JCV, does not share receptor specificity with SV40 on human glial cells. J Neurovirol 1998; 4(1):49–58.

    PubMed  CAS  Google Scholar 

  88. Drachenberg CB, Papadimitriou JC, Wali R et al. BK polyoma virus allograft nephropathy: Ultrastructural features from viral cell entry to lysis. Am J Transplant 2003; 3(11):1383–92.

    PubMed  Google Scholar 

  89. Schweighardt B, Atwood WJ. Virus receptors in the human central nervous system. J Neurovirol 2001; 7(3):187–95.

    PubMed  CAS  Google Scholar 

  90. Atwood WJ. A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: Implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy. J Neurovirol 2001; 7(4):307–10.

    PubMed  CAS  Google Scholar 

  91. Baum S, Ashok A, Gee G et al. Early events in the life cycle of JC virus as potential therapeutic targets for the treatment of progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9(Suppl 1):32–7.

    PubMed  CAS  Google Scholar 

  92. Anderson HA, Chen Y, Norkin LC. Bound simian virus 40 translocates to caveolin-enriched membrane domains, and its entry is inhibited by drugs that selectively disrupt caveolae. Mol Biol Cell 1996;7(11):1825–34.

    PubMed  CAS  Google Scholar 

  93. Chen Y, Norkin LC. Extracellular simian virus 40 transmits a signal that promotes virus enclosure within caveolae. Exp Cell Res 1999; 246(1):83–90.

    PubMed  CAS  Google Scholar 

  94. Gilbert JM, Goldberg IG, Benjamin TL. Cell penetration and trafficking of polyomavirus. J Virol 2003; 77(4):2615–22.

    PubMed  CAS  Google Scholar 

  95. Portolani M, Pietrosemoli P, Cermelli C et al. Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase. Antiviral Res 1988; 9(3):205–18.

    PubMed  CAS  Google Scholar 

  96. Chen Y, Freund R, Listerud M et al. Retinoic acid inhibits transformation by preventing phosphatidylinositol 3-kinase dependent activation of the c-fos promoter. Oncogene 1999; 18(1):139–48.

    PubMed  CAS  Google Scholar 

  97. Talmage DA, Listerud M. Retinoic acid suppresses polyoma virus transformation by inhibiting transcription of the c-fos proto-oncogene. Oncogene 1994; 9(12):3557–63.

    PubMed  CAS  Google Scholar 

  98. Ferrazzi E, Peracchi M, Biasolo MA et al. Antiviral activity of gyrase inhibitors norfloxacin, coumermycin A1 and nalidixic acid. Biochem Pharmacol 1988; 37(9):1885–6.

    PubMed  CAS  Google Scholar 

  99. Tarabek J, Zemla J, Bacik I. Northern blot hybridization analysis of polyoma virus-specific RNA synthesized under the block of virus replication by 5-bromo-2′-deoxyuridine. Acta Virol 1991; 35(4):305–12.

    PubMed  CAS  Google Scholar 

  100. Andrei G, Snoeck R, Vandeputte M et al. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997; 41(3):587–93.

    PubMed  CAS  Google Scholar 

  101. De Clercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology 1997; 40(5–6):295–303.

    PubMed  Google Scholar 

  102. De Clercq E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1997; 10(4):674–93.

    PubMed  Google Scholar 

  103. Foster PF, Wright F, McLean D et al. Leflunomide administration as an adjunct in treatment of BK-polyoma viral disease in kidney allografts [abstract]. Am J Transplant 2003; 3(Suppl 5):421.

    Google Scholar 

  104. Snoeck R, Andrei G, Lilja H et al. Activity of malononitrilamide compounds against murine and simian polyomavirus. Geneva, Switzerland: Paper presented at: 5th International Conference on New Trends in Clinical and Experimental Immunosuppression 2002, [abstract].

    Google Scholar 

  105. Ma DD, Doan TL. Antisense oligonudeotide therapies: Are they the “magic bullets”? Ann Intern Med 1994; 120(2):161–3.

    PubMed  CAS  Google Scholar 

  106. Levy RM, Ward S, Schalgeter K et al. Alternative delivery systems for antiviral nucleosides and antisense oligonucleotides to the brain. J Neurovirol 1997; 3(Suppl 1):S74–5.

    PubMed  Google Scholar 

  107. Package insert. Vistide® (cidofovir injection). Foster City, CA: Gilead Sciences Inc., 2000.

    Google Scholar 

  108. Portilla J, Boix V, Roman F et al. Progressive multifocal leukoencephalopathy treated with cidofovir in HIV-infected patients receiving highly active anti-retroviral therapy. J Infect 2000; 41(2):182–4.

    PubMed  CAS  Google Scholar 

  109. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999; 36(2):127–43.

    PubMed  CAS  Google Scholar 

  110. Cassady KA, Whitley RJ. New therapeutic approaches to the alphaherpesvirus infections. J Antimicrob Chemother 1997; 39(2):119–28.

    PubMed  CAS  Google Scholar 

  111. Package insert. Arava® Tablets (leflunomide). Kansas City, MO: Aventis Pharmaceuticals Inc., 2003.

    Google Scholar 

  112. Hou J, Major EO. The efficacy of nucleoside analogs against JC virus multiplication in a persis tently infected human fetal brain cell line. J Neurovirol 1998; 4(4):451–6.

    PubMed  CAS  Google Scholar 

  113. Houston S, Roberts N, Mashinter L. Failure of cidofovir therapy in progressive multifocal leukoencephalopathy unrelated to human immunodeficiency virus. Clin Infect Dis 2001; 32(1):150–2.

    PubMed  CAS  Google Scholar 

  114. Dodge RT. A case study: The use of cidofovir for the management of progressive multifocal leukoencephalopathy. J Assoc Nurses AIDS Care 1999; 10(4):70–4.

    PubMed  CAS  Google Scholar 

  115. Cardenas RL, Cheng KH, Sack K. The effects of cidofovir on progressive multifocal leukoencephalopathy: An MRI case study. Neuroradiology 2001; 43(5):379–82.

    PubMed  CAS  Google Scholar 

  116. Salmaggi A, Maccagnano E, Castagna A et al. Reversal of CSF positivity for JC virus genome by cidofovir in a patient with systemic lupus erythematosus and progressive multifocal leukoencephalopathy. Neurol Sci 2001; 22(1):17–20.

    PubMed  CAS  Google Scholar 

  117. Razonablc RR, Aksamit AJ, Wright AJ et al. Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. Mayo Clin Proc 2001; 76(11):1171–5.

    Google Scholar 

  118. Haider S, Nafziger D, Gutierrez JA et al. Progressive multifocal leukoencephalopathy and idiopathic CD4+lymphocytopenia: A case report and review of reported cases. Clin Infect Dis 2000; 31(4):E20–2.

    PubMed  CAS  Google Scholar 

  119. Zimmermann T, Stingele K, Hartmann M et al. Successful treatment of aids related PML with HAART and cidofovir. Eur J Med Res 2001; 6(5):190–62.

    PubMed  CAS  Google Scholar 

  120. Roberts MT, Carmichael A, Lever AM. Prolonged survival in AIDS-related progressive multifocal leucoencephalopathy following anti-retroviral therapy and cidofovir. Int J Antimicrob Agents 2003; 21(4):347–9.

    PubMed  CAS  Google Scholar 

  121. Antinori A, Cingolani A, Lorenzini P et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: Data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9(Suppl 1):47–53.

    PubMed  CAS  Google Scholar 

  122. Kiewe P, Seyfert S, Korper S et al. Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma 2003; 44(10):1815–8.

    PubMed  Google Scholar 

  123. De Luca A, Giancola ML, Ammassari A et al. Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. Aids 2000; 14(14):F117–21.

    PubMed  Google Scholar 

  124. De Luca A, Giancola ML, Ammassari A et al. Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. J Neurovirol 2001; 7(4):364–8.

    PubMed  Google Scholar 

  125. Taoufik Y, Delfraissy JF, Gasnault J. Highly active antiretroviral therapy does not improve survival of patients with high JC virus load in the cerebrospinal fluid at progressive multifocal leukoencephalopathy diagnosis. Aids 2000; 14(6):758–9.

    PubMed  CAS  Google Scholar 

  126. Held TK, Biel SS, Nitsche A et al. Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir. Bone Marrow Transplant 2000; 26(3):347–50.

    PubMed  CAS  Google Scholar 

  127. Hatakeyama N, Suzuki N, Kudoh T et al. Successful cidofovir treatment of adenovirus-associated hemorrhagic cystitis and renal dysfunction after allogenic bone marrow transplant. Pediatr Infect Dis J 2003; 22(10):928–9.

    PubMed  Google Scholar 

  128. Bjorang O, Tveitan H, Midtvedt K et al. Treatment of polyomavirus infection with cidofovir in a renal-transplant recipient. Nephrol Dial Transplant 2002; 17(11):2023–5.

    PubMed  CAS  Google Scholar 

  129. Keller LS, Peh CA, Nolan J et al. BK transplant nephropathy successfully treated with cidofovir. Nephrol Dial Transplant 2003; 18(5):1013–4.

    PubMed  Google Scholar 

  130. Kadambi PV, Josephson MA, Williams J et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 2003; 3(2): 186–91.

    PubMed  Google Scholar 

  131. Vats A, Shapiro R, Singh Randhawa P et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 2003; 75(1):105–12.

    PubMed  CAS  Google Scholar 

  132. Scantlebury V, Shapiro R, Randhawa P et al. Cidofovir: A method of treatment for BK virus-associated transplant nephropathy. Graft 2002; 5(Suppl):S82–7.

    CAS  Google Scholar 

  133. Mayer DF, Kushwaha SS. Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases. Curr Opin Rheumatol 2003; 15(3):219–25.

    PubMed  CAS  Google Scholar 

  134. Sanders S, Harisdangkul V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci 2002; 323(4):190–3.

    PubMed  Google Scholar 

  135. Goldenberg MM. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Clin Ther 1999; 21(11):1837–52; discussion 21.

    PubMed  CAS  Google Scholar 

  136. Lednicky JA, Stewart AR, Jenkins III JJ et al. SV40 DNA in human osteosarcomas shows sequence variation among T-antigen genes. Int J Cancer 1997; 72(5):791–800.

    PubMed  CAS  Google Scholar 

  137. Waldman WJ, Knight DA, Blinder L et al. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999; 42(5–6):412–8.

    PubMed  CAS  Google Scholar 

  138. Waldman WJ, Knight DA, Lurain NS et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 1999; 68(6):814–25.

    PubMed  CAS  Google Scholar 

  139. Williams JW, Mital D, Chong A et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002; 73(3):358–66.

    PubMed  CAS  Google Scholar 

  140. Kerr DA, Chang CF, Gordon J et al. Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology 1993; 196(2):612–8.

    PubMed  CAS  Google Scholar 

  141. Package insert. Hycamtin® (topotecan hydrochloride). Research Triangle Park, North Carolina: GlaxoSmithKline Pharmaceuticals, 2003.

    Google Scholar 

  142. Rand KH, Johnson KP, Rubinstein LJ et al. Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: Use of virus-containing cells in the urine to assess response to therapy. Ann Neurol 1977; 1(5):458–62.

    PubMed  CAS  Google Scholar 

  143. Package Insert. Cytarabine. Irvine, California: GensiaSicor Pharmaceuticals, 1999.

    Google Scholar 

  144. Nicoli F, Chave B, Peragut JC et al. Efficacy of cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 1992; 339(8788):306.

    PubMed  CAS  Google Scholar 

  145. O’Riordan T, Daly PA, Hutchinson M et al. Progressive multifocal leukoencephalopathy-remission with cytarabine. J Infect 1990; 20(1):51–4.

    PubMed  CAS  Google Scholar 

  146. Steiger MJ, Tarnesby G, Gabe S et al. Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol 1993; 33(4):407–11.

    PubMed  CAS  Google Scholar 

  147. Aksamit AJ. Treatment of nonAIDS progressive multifocal leukoencephaiopathy with cytosine arabinoside. J Neurovirol 2001; 7(4):386–90.

    PubMed  CAS  Google Scholar 

  148. Levy RM, Major E, Ali MJ et al. Convection-enhanced intraparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephaiopathy (PML). J Neurovirol 2001; 7(4):382–5.

    PubMed  CAS  Google Scholar 

  149. Hoffmann RP, Lewis IK. Vidarabine (Drug Evaluation). In: Hutchinson TA, Shahan DR, eds. DRUGDEX® System. MICROMEDEX, Greenwood Village, Colorado (Edition expires 9/2002).

    Google Scholar 

  150. Chapman C, Flower AJ, Durrant ST. The use of vidarabine in the treatment of human polyomavirus associated acute haemorrhagic cystitis. Bone Marrow Transplant 1991; 7(6):481–3.

    PubMed  CAS  Google Scholar 

  151. Seabra C, Perez-Simon JA, Sierra M et al. Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic stem cell transplantation. Bone Marrow Trans plant 2000; 26(11): 1229–30.

    CAS  Google Scholar 

  152. Vianelli N, Renga M, Azzi A et al. Sequential vidarabine infusion in the treatment of polyoma virus-associated acute haemorrhagic cystitis late after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25(3):319–20.

    PubMed  CAS  Google Scholar 

  153. Puliyanda D, Amet N, Archana D et al. IVIG contains antibodies reactive with polyomaviruses BK and may represent a therapeutic option for BK virus and may represent a therapeutic option for BK nephropathy. Am J Transplant 2003; 3(Suppl 5):393 (Abstract 941).

    Google Scholar 

  154. Casadei DH, Rial MDC, Opelz G et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71(1):53–8.

    PubMed  CAS  Google Scholar 

  155. Cibrik DM, O Toole JF, Norman SP et al. IVIG for the treatment of BK nephropathy. Am J Transplant 2003; 3(Suppl 5):370 (Abstract 850).

    Google Scholar 

  156. Berger JR. Progressive Multifocal Leukoencephalopathy. Curr Treat Options Neurol 2000; 2(4):361–8.

    PubMed  Google Scholar 

  157. Huang SS, Skolasky RL, Dal Pan GJ et al. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: An observational study. J Neurovirol 1998; 4(3):324–32.

    PubMed  CAS  Google Scholar 

  158. Clifford DB. Challenges for clinical trials to treat progressive multifocal leukoencephalopathy. J Neurovirol 2003; 9(Suppl 1):68–72.

    PubMed  CAS  Google Scholar 

  159. Cheeseman SH, Black PH, Rubin RH et al. Interferon and BK Papovavirus—clinical and laboratory studies. J Infect Dis 1980; 141(2): 157–61.

    PubMed  CAS  Google Scholar 

  160. Ramos E, Drachenberg CB, Portocarrero M et al. BK virus nephropathy diagnosis and treatment: Experience at the University of Maryland Renal Transplant Program. In: Cecka J, Terasaki P, eds. Clinical Transplants 2002. Los Angeles: UCLA Immunogenetics Center; 2003:143–53.

    Google Scholar 

  161. Mayr M, Nickeleit V, Hirsch HH et al. Polyomavirus BK nephropathy in a kidney transplant recipient: Critical issues of diagnosis and management. Am J Kidney Dis 2001; 38(3):E13.

    PubMed  CAS  Google Scholar 

  162. Scantlebury V, Shapiro R, Justin G et al. Graft function after diagnosis of BK virus in adult kidney transplant recipients under tacrolimus-based immunosuppression [abstract]. Am J Transpl 2001; 1(Suppl 1):404.

    Google Scholar 

  163. Loertscher R, Suri R, Lipman M et al. Deliberate reduction of immunosuppression benefits patients with polyoma BK virus infection in kidney allografts [abstract]. Am J Transpl 2002; 2(Suppl 3):262.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA

    Julie Roskopf Pharm D. & Robert J. Stratta M.D.

  2. Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

    Jennifer Trofe Pharm D. BCPS

  3. Mayo Clinic Transplant Center, Mayo Clinic - College of Medicine, Jacksonville, Florida, USA

    Nasimul Ahsan M.D., FACP

Authors
  1. Julie Roskopf Pharm D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Trofe Pharm D. BCPS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert J. Stratta M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nasimul Ahsan M.D., FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mayo Clinic Transplant Center, Mayo Clinic - College of Medicine, Jacksonville, Florida, USA

    Nasimul Ahsan M.D., FACP

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Eurekah.com and Springer Science+Business Media

About this chapter

Cite this chapter

Roskopf, J., Trofe, J., Stratta, R.J., Ahsan, N. (2006). Pharmacotherapeutic Options for the Management of Human Polyomaviruses. In: Ahsan, N. (eds) Polyomaviruses and Human Diseases. Advances in Experimental Medicine and Biology, vol 577. Springer, New York, NY. https://doi.org/10.1007/0-387-32957-9_17

Download citation

Publish with us

Policies and ethics

Search

Navigation